Oncotarget

Research Papers: Gerotarget (Focus on Aging):

Virtual screening, optimization, and identification of a novel specific PTP-MEG2 Inhibitor with potential therapy for T2DM

Meiyan Wang, Xiaobo Li, Lei Dong, Xiubo Chen, Weiren Xu and Runling Wang _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:50828-50834. https://doi.org/10.18632/oncotarget.10341

Metrics: PDF 866 views  |   HTML 1397 views  |   ?  


Abstract

Meiyan Wang1,*, Xiaobo Li1,2,*, Lei Dong2,*, Xiubo Chen3, Weiren Xu4 and Runling Wang1

1 Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, China

2 Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA

3 Tianjin Medical University Eye Hospital, Tianjin, China

4 Tianjin Key Laboratory of Molecular Design and Drug Discovery, Tianjin Institute of Pharmaceutical Research, Tianjin, China

* These authors have contributed equally to this work

Correspondence to:

Runling Wang, email:

Keywords: PTP-MEG2 inhibitor; core hopping; diabetes; selectivity; molecular dynamics simulation; Gerotarget

Received: March 22, 2016 Accepted: June 03, 2016 Published: June 30, 2016

Abstract

Megakaryocyte protein tyrosine phosphatase 2 (PTP-MEG2) is a tyrosine phosphatase expressed in megakaryocytic cells, and causes insulin sensitization when down regulated. Therefore, specific inhibitors of PTP-MEG2 are potential candidates for novel Type 2 Diabetes (T2DM)therapy. In this study, we discovered PTP-MEG2 inhibitors using high throughput and virtual screening (HTS/VS) and structural optimization in silicon.Eight compound-candidates were identified from the interactions with PTP-MEG2, protein tyrosine phosphatase 1B (PTP1B) and T cell protein tyrosine phosphatase (TCPTP). Results from enzymatic assays show compounds 4a and 4b inhibited PTP-MEG2 activity with an IC50 of 3.2 μM and 4.3 μM, respectively. Further, they showed a 7.5 and 5.5 fold change against PTP1B and TCPTP, respectively. We propose compounds 4a and 4b are PTP-MEG2 inhibitors with potential therapeutic use in T2DM treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10341